|
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) |
|
Zynerba Pharmaceuticals Inc
ZYNE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Zynerba Pharmaceuticals Inc 's sales fell
in the second quarter of 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -8.1 %
Zynerba Pharmaceuticals Inc net loss increased from $-10 millions, to $-11 millions in second quarter of 2023,
• More on ZYNE's Growth
|
|
Zynerba Pharmaceuticals Inc realized a net loss in trailing twelve months.
Zynerba Pharmaceuticals Inc realized cash reduction of $ -0.53 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on ZYNE's Valuation
|
|
|
|
|
Zynerba Pharmaceuticals Inc realized net loss in trailing twelve months.
Zynerba Pharmaceuticals Inc realized cash outflow of $ -0.53per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
Zynerba Pharmaceuticals Inc Price to Book Ratio is at 2.25 lower than Industry Avg. of 35.2. and higher than S&P 500 Avg. of 0.01
• More on ZYNE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com